Janux Therapeutics Inc
Research Janux Therapeutics Inc (JANX) on Bullrun: market cap USD 1.14B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerJANX
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 1.14B
- Financial periodQ2 2026
- RevenueUSD 10.27M
- Net income-USD 21.97M
- Free cash flowUSD 12.28M
Valuation Snapshot
latest market cap is USD 1.14B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 10.00M | -USD 113.63M | -USD 83.28M | n/a | -1.83 | USD 52.33M | USD 22.14M | USD 956.82M |
| FY2024 | USD 10.59M | -USD 68.99M | -USD 44.17M | n/a | -1.28 | USD 430.61M | USD 23.03M | USD 1.02B |
| FY2023 | USD 8.08M | -USD 58.29M | -USD 52.43M | n/a | -1.32 | USD 19.21M | USD 24.54M | USD 344.35M |
| FY2022 | USD 8.61M | -USD 63.06M | -USD 49.37M | n/a | -1.52 | USD 51.43M | USD 23.36M | USD 320.74M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 1.14B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 833.30M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 3.16B | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 495.20M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 548.70M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 813.73M | n/a | n/a | n/a |
About Janux Therapeutics Inc
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Janux Therapeutics Inc's market cap?
Janux Therapeutics Inc's market capitalization is USD 1.14B.
What does Janux Therapeutics Inc do?
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer.